Infectious Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By End Use, By Region, and By Competition, 2020-2030F

Description

The Global Infectious Disease Therapeutics Market, valued at USD 67.64 Billion in 2024, is projected to experience a CAGR of 7.74% to reach USD 105.80 Billion by 2030. The Global Infectious Disease Therapeutics Market encompasses pharmaceutical agents and medical interventions designed for the prevention, treatment, and management of illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites. Key drivers supporting market expansion include the increasing global prevalence of infectious diseases, the persistent challenge of antimicrobial resistance, and growing investments in research and development to address unmet medical needs. Further impetus comes from continuous advancements in diagnostic technologies enabling earlier and more precise disease identification.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 67.64 Billion
Market Size 2030	USD 105.80 Billion
CAGR 2025-2030	7.74%
Fastest Growing Segment	Hospitals
Largest Market	North America

Key Market Drivers

The increasing global burden of infectious diseases fundamentally drives market expansion, creating persistent and widespread demand for effective treatments and preventative measures. Diseases like tuberculosis and malaria continue to exact a significant toll on global health, necessitating ongoing research and development into novel pharmacological agents and improved therapeutic strategies. The sheer scale of these challenges ensures a consistent market for diagnostics, drugs, and vaccines, as healthcare systems grapple with endemic infections and outbreaks. According to the World Health Organization, in its Global Tuberculosis Report 2023, an estimated 10.6 million people fell ill with tuberculosis worldwide in 2022, underscoring the critical need for continued therapeutic interventions. This sustained disease pressure compels pharmaceutical companies to invest in developing new therapies to address unmet medical needs.

Key Market Challenges

A significant challenge impeding the growth of the Global Infectious Disease Therapeutics Market is the substantial costs associated with drug discovery and development. Bringing new pharmaceutical agents from initial research to market approval demands extensive financial outlays for preclinical studies, multiple phases of clinical trials, and manufacturing infrastructure. This immense capital requirement significantly raises the barrier to entry for innovators and imposes considerable financial risk on companies, influencing strategic decisions about which therapeutic areas to prioritize.

Key Market Trends

The application of Artificial Intelligence (AI) in drug discovery is significantly reshaping the development landscape for infectious disease therapeutics. AI algorithms are increasingly employed to accelerate the identification of novel drug targets, optimize compound synthesis, and predict drug efficacy and toxicity with greater precision and speed, thereby reducing the time and cost associated with traditional drug development. This technological integration is poised to streamline the discovery of urgently needed treatments for evolving pathogens. According to a survey from Rackspace Technology and Dell/VMware, conducted in October 2023, two out of three pharmaceutical companies (67%) planned to increase their investment in information technology, including artificial intelligence, over the subsequent 12 months. This substantial industry-wide commitment to AI is expected to catalyze innovation across all therapeutic areas, including infectious diseases, by enhancing the efficiency of research and development pipelines.

Key Market Players

Novartis AG
Gilead Sciences Inc
GSK PLC
Johnson & Johnson Innovative Medicine
F Hoffmann-La Roche AG
BioCryst Pharmaceuticals Inc
Merck & Co Inc
Boehringer Ingelheim International GmbH

Report Scope:

In this report, the Global Infectious Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infectious Disease Therapeutics Market, By Disease Type:

HIV
Hepatitis
Influenza
TB
Malaria
HPV
Others

Infectious Disease Therapeutics Market, By End Use:

Hospitals
Clinics
Others

Infectious Disease Therapeutics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Infectious Disease Therapeutics Market.

Available Customizations:

Global Infectious Disease Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Infectious Disease Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Disease Type (HIV, Hepatitis, Influenza, TB, Malaria, HPV, Others)
- 5.2.2. By End Use (Hospitals, Clinics, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Infectious Disease Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Disease Type
- 6.2.2. By End Use
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Infectious Disease Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Disease Type
    - 6.3.1.2.2. By End Use
- 6.3.2. Canada Infectious Disease Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Disease Type
    - 6.3.2.2.2. By End Use
- 6.3.3. Mexico Infectious Disease Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Disease Type
    - 6.3.3.2.2. By End Use

7. Europe Infectious Disease Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Disease Type
- 7.2.2. By End Use
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Infectious Disease Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Disease Type
    - 7.3.1.2.2. By End Use
- 7.3.2. France Infectious Disease Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Disease Type
    - 7.3.2.2.2. By End Use
- 7.3.3. United Kingdom Infectious Disease Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Disease Type
    - 7.3.3.2.2. By End Use
- 7.3.4. Italy Infectious Disease Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Disease Type
    - 7.3.4.2.2. By End Use
- 7.3.5. Spain Infectious Disease Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Disease Type
    - 7.3.5.2.2. By End Use

8. Asia Pacific Infectious Disease Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Disease Type
- 8.2.2. By End Use
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Infectious Disease Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Disease Type
    - 8.3.1.2.2. By End Use
- 8.3.2. India Infectious Disease Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Disease Type
    - 8.3.2.2.2. By End Use
- 8.3.3. Japan Infectious Disease Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Disease Type
    - 8.3.3.2.2. By End Use
- 8.3.4. South Korea Infectious Disease Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Disease Type
    - 8.3.4.2.2. By End Use
- 8.3.5. Australia Infectious Disease Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Disease Type
    - 8.3.5.2.2. By End Use

9. Middle East & Africa Infectious Disease Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Disease Type
- 9.2.2. By End Use
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Infectious Disease Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Disease Type
    - 9.3.1.2.2. By End Use
- 9.3.2. UAE Infectious Disease Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Disease Type
    - 9.3.2.2.2. By End Use
- 9.3.3. South Africa Infectious Disease Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Disease Type
    - 9.3.3.2.2. By End Use

10. South America Infectious Disease Therapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Disease Type
- 10.2.2. By End Use
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Infectious Disease Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Disease Type
    - 10.3.1.2.2. By End Use
- 10.3.2. Colombia Infectious Disease Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Disease Type
    - 10.3.2.2.2. By End Use
- 10.3.3. Argentina Infectious Disease Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Disease Type
    - 10.3.3.2.2. By End Use

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Infectious Disease Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Novartis AG
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Gilead Sciences Inc
15.3. GSK PLC
15.4. Johnson & Johnson Innovative Medicine
15.5. F Hoffmann-La Roche AG
15.6. BioCryst Pharmaceuticals Inc
15.7. Merck & Co Inc
15.8. Boehringer Ingelheim International GmbH